JOHNS HOPKINS MEDICINE IMAGE: THE HIGH MOBILITY GROUP A1 (HMGA1) PROTEIN FUNCTIONS AS A “MOLECULAR SWITCH” THAT “FLIPS ON” EXPRESSION AND SECRETION OF A CRITICAL GROWTH FACTOR, CALLED FGF19, IN PANCREATIC CANCER. TOGETHER WITH HMGA1, FGF19 PROMOTES TUMOR PROGRESSION AND FORMATION OF A DENSE WALL-LIKE STRUCTURE CALLED THE “STROMA”, WHICH PREVENTS THERAPY FROM REACHING TUMOR...
by Melissa Rohman, Northwestern University Mazhar Adli, PhD, associate professor of Obstetrics and Gynecology in the Division of Reproductive Science in Medicine and senior author of the study published in Developmental Cell. Credit: Northwestern University Northwestern Medicine investigators have discovered a potential therapeutic target for the most common type of pancreatic cancer, according to a study published...
by Institute of Cancer Research Figure 1. Characterization of baseline effects of pHIFU treatments on KPC tumors. (a) Treatment sequencing regime used in this study. Subjects were injected IP with a combination of anti-CTLA-4 and anti-PD-1 3 days before pHIFU exposures, on exposure day (immediately after pHIFU) and every 3 days thereafter until the time...
UNIVERSITY OF CAMBRIDGE Faulty versions of the BRCA1 and BRCA2 genes are well known to increase the risk of breast cancer in men and women, and in ovarian cancer. Now BRCA1 and BRCA2 have been linked to several other cancers, including those that affect men. A study published today in the Journal of Clinical Oncology has provided...
by Massachusetts General Hospital Pancreatic cells can become cancerous (magenta) when an inflammatory molecule called IL-33 activates signals within the pancreatic cells that promote their abnormal growth, investigators at Massachusetts General Hospital have found. The research, which is published in The EMBO Journal, could lead to new strategies to prevent certain cancers. Credit: Jong Ho Park, PhD...
